Talzenna approved by FDA: FDA Approves... - Prostate Cancer N...

Prostate Cancer Network

5,231 members3,293 posts

Talzenna approved by FDA

Magnus1964 profile image
3 Replies

FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer

Significant radiographic progression-free survival seen for homologous recombination repair gene mutation, including with BRCA mutation

HealthDay

MONDAY, June 26, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

The approval was based on a trial in which 399 patients with HRR gene-mutated mCRPC were randomly assigned (1:1) to receive enzalutamide 160 mg daily plus either talazoparib 0.5 mg or placebo daily.

The results of the trial showed statistically significant improvement in radiographic progression-free survival (rPFS) for Talzenna with enzalutamide versus placebo. Median rPFS was not reached in the Talzenna group versus 13.8 months with placebo (hazard ratio, 0.45; 95 percent confidence interval, 0.33 to 0.61; P < 0.0001). For 155 patients with BRCA-mutated mCRPC, the hazard ratio for rPFS was 0.20 (95 percent confidence interval, 0.11 to 0.36), but for HRR gene-mutated mCRPC without BRCA mutations, the hazard ratio was 0.72 (95 percent confidence interval, 0.49 to 1.07).

Recommended dosing is 0.5 mg orally once daily for Talzenna in combination with enzalutamide (160 mg orally daily) until disease progression or unacceptable toxicity. Patients receiving this combination should also receive a gonadotropin-releasing hormone analog concurrently or should have had bilateral orchiectomy.

The most common adverse reactions (≥10 percent) included decreased hemoglobin, neutrophils, lymphocytes, platelets, calcium, sodium, phosphate, magnesium, and potassium, as well as nausea, decreased appetite, fractures, dizziness, increased bilirubin, and dysgeusia. A blood transfusion was needed among 39 percent of patients treated with Talzenna with enzalutamide, including 22 percent who required multiple transfusions.

Approval of Talzenna was granted to Pfizer.

Written by
Magnus1964 profile image
Magnus1964
To view profiles and participate in discussions please or .
Read more about...
3 Replies
Mw921000000 profile image
Mw921000000

Do we know if Talzenna can be used if xtandi resistance has already occurred?

Magnus1964 profile image
Magnus1964

I am reading you question right, I don't think Talzenna is a re-sensitizing agent for Xtandi or any ADT drug

pretty harsh SEs

Not what you're looking for?

You may also like...

FDA approves Erleada for metastatic hormone-sensitive prostate cancer

Joining Zytiga, and docetaxel. Probably Xtandi too very soon....
Tall_Allen profile image

Confused by 2nd Opinion From Johns Hopkins

I will try to be as concise as possible. I just turned 70. In December of last year my primary care...
Abraxis49 profile image

Are teeth affected by ADT or Xtandi?

after about 2 months of Lupron and Xtandi my teeth are tender and sore. Any correlation?

ECE and CRIBRIFORM FOUND IN PATH REVIEW OF MSK BIOPSY BY UCSF

I am scheduled for SBRT at UCLA for 1/12/ 2023. However , UCSF did a path review of MSK's Biopsy...
JWS13 profile image

Advice request for dealing with expected incontinence after prostate removal by Da Vinci

Hello all I am looking for some detail on what supplies i should stock up on at home prior to...
Fox2018 profile image

Moderation team

Bethishere profile image
BethishereAdministrator
Number6 profile image
Number6Administrator
Darryl profile image
DarrylPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.